The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.

Humans Erythropoietin / therapeutic use Receptors, Erythropoietin Glaucoma / drug therapy Epoetin Alfa Retinal Ganglion Cells
erythropoietin glaucoma neuroprotection optic neuropathy retinal ganglion cell

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Dec 2022
Historique:
received: 25 10 2022
revised: 06 12 2022
accepted: 14 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. In human retinal tissues, EPO receptors (EPORs) are expressed in the photoreceptor cells, retinal pigment epithelium, and retinal ganglion cell layer. Studies have suggested its potential therapeutic effects in many neurodegenerative diseases, including glaucoma. In this review, we discuss the correlation between glaucoma and EPO, physiology and potential neuroprotective function of the EPO/EPOR system, and latest evidence for the treatment of glaucoma with EPO.

Identifiants

DOI: 10.3390/ijms232416038 PMID: 36555679 PMC: PMC9784015
pubmed: 36555679
pii: ijms232416038
doi: 10.3390/ijms232416038
pmc: PMC9784015
pii:
doi:

Substances chimiques

Erythropoietin 11096-26-7
Receptors, Erythropoietin 0
Epoetin Alfa 64FS3BFH5W

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Tri-Service General Hospital
ID : TSGH-E-111239
Organisme : National Defense Medical Center
ID : MND-MAB-110-131 and MND-MAB-D-111137

Références

Cancer Cell. 2015 Nov 9;28(5):610-622
pubmed: 26481148
J Neuroinflammation. 2016 Feb 15;13:39
pubmed: 26876380
Nature. 2001 Aug 9;412(6847):641-7
pubmed: 11493922
Curr Mol Med. 2013 Nov;13(9):1419-31
pubmed: 23971737
Blood Cells. 1987;13(1-2):217-26
pubmed: 3478108
Int J Mol Sci. 2019 Dec 05;20(24):
pubmed: 31817513
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4044-9
pubmed: 11259643
J Clin Med. 2018 Feb 02;7(2):
pubmed: 29393890
J Cereb Blood Flow Metab. 1999 Jun;19(6):643-51
pubmed: 10366194
Surv Ophthalmol. 2014 Jul-Aug;59(4):434-47
pubmed: 24837853
Eye Brain. 2021 Jan 18;13:21-28
pubmed: 33500674
Ophthalmic Res. 2016 Jul;56(2):104-10
pubmed: 27077922
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Curr Opin Hematol. 2010 May;17(3):169-76
pubmed: 20173635
Brain Res. 2005 Jul 19;1050(1-2):15-26
pubmed: 15979589
Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
J Neurosci Res. 2003 Oct 1;74(1):37-51
pubmed: 13130504
Front Immunol. 2021 Jun 30;12:697796
pubmed: 34276689
Eur J Pharm Sci. 2011 Jul 17;43(4):334-42
pubmed: 21621611
BMC Res Notes. 2009 Nov 25;2:234
pubmed: 19930719
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8
pubmed: 17325165
Exp Eye Res. 2009 Nov;89(5):735-40
pubmed: 19591826
Clin Investig. 1994;72(6 Suppl):S36-43
pubmed: 7950171
Clin Perinatol. 2015 Sep;42(3):469-81
pubmed: 26250911
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Mol Pharmacol. 2003 Sep;64(3):557-69
pubmed: 12920191
Hum Mol Genet. 2011 Jun 1;20(11):2251-62
pubmed: 21421996
Biomolecules. 2021 Apr 15;11(4):
pubmed: 33920974
Physiol Rev. 1992 Apr;72(2):449-89
pubmed: 1557429
Diabetes Care. 2008 Jun;31(6):1189-94
pubmed: 18332162
Arch Ophthalmol. 2004 Sep;122(9):1348-56
pubmed: 15364715
N Engl J Med. 2002 Dec 12;347(24):1968-70
pubmed: 12477950
Neural Regen Res. 2012 Feb 5;7(4):295-301
pubmed: 25806072
Vitam Horm. 2017;105:79-100
pubmed: 28629526
Cell Mol Neurobiol. 2008 Feb;28(2):317-29
pubmed: 17554621
FASEB J. 2005 Feb;19(2):249-51
pubmed: 15556972
PLoS One. 2020 Apr 17;15(4):e0223208
pubmed: 32302311
J Glaucoma. 2007 Dec;16(8):645-8
pubmed: 18091448
J Investig Med. 2011 Oct;59(7):1067-72
pubmed: 21307776
Ophthalmologe. 2010 Apr;107(4):347-53
pubmed: 19787355
PLoS One. 2013;8(1):e55291
pubmed: 23383140
Blood. 1999 Apr 15;93(8):2627-36
pubmed: 10194442
Int J Ophthalmol. 2011;4(1):40-3
pubmed: 22553606
Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80
pubmed: 8897823
J Clin Invest. 2008 Feb;118(2):526-33
pubmed: 18219389
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14907-12
pubmed: 15456912
Kidney Int Suppl. 2007 Nov;(107):S10-5
pubmed: 17943138
J Neurochem. 2021 Sep;158(5):1032-1057
pubmed: 34278579
J Glaucoma. 2015 Mar;24(3):214-8
pubmed: 23835669
Curr Eye Res. 2010 Aug;35(8):680-4
pubmed: 20673044
Trends Endocrinol Metab. 1999 Dec;10(1):18-23
pubmed: 10322390
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):23
pubmed: 32785675
Biomed Hub. 2018 Jul 13;3(2):1-11
pubmed: 31988957
Mol Ther. 2016 Feb;24(2):230-239
pubmed: 26502777
J Biol Chem. 1999 Aug 6;274(32):22165-9
pubmed: 10428780
Exp Neurol. 2007 May;205(1):48-55
pubmed: 17328893
Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1831-40
pubmed: 25813241
Genes Dev. 2002 Jun 15;16(12):1466-71
pubmed: 12080085
J Neurochem. 2016 Nov;139(4):596-609
pubmed: 27488413
BMC Nephrol. 2021 May 31;22(1):203
pubmed: 34059008
Exp Cell Res. 2019 Jan 15;374(2):266-273
pubmed: 30576679
Am J Pathol. 2014 Apr;184(4):1230-1239
pubmed: 24630601
High Alt Med Biol. 2020 Mar;21(1):92-98
pubmed: 31977247
Oncologist. 2004;9 Suppl 5:18-30
pubmed: 15591419
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):907-19
pubmed: 19741249
Front Immunol. 2014 Oct 22;5:523
pubmed: 25374571
Hum Gene Ther. 2011 Oct;22(10):1191-200
pubmed: 21542676
Neurochem Res. 2021 Apr;46(4):732-739
pubmed: 33521906
Mol Med Rep. 2014 Dec;10(6):2979-84
pubmed: 25269825
Blood Rev. 2013 Jan;27(1):41-53
pubmed: 23291219
Nat Med. 2002 Jul;8(7):718-24
pubmed: 12068288
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Invest Ophthalmol Vis Sci. 2004 May;45(5):1514-22
pubmed: 15111610
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31
pubmed: 10984541
Mol Vis. 2012;18:1991-5
pubmed: 22876126
Biomed Rep. 2020 Nov;13(5):40
pubmed: 32934813
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8
pubmed: 8171022
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5680-4
pubmed: 2062846
Clinics (Sao Paulo). 2018;73:e161
pubmed: 29694605
N Engl J Med. 2005 Aug 25;353(8):782-92
pubmed: 16120858
Neuroscientist. 2004 Apr;10(2):93-8
pubmed: 15070483
Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1859-67
pubmed: 17828550
J Ocul Pharmacol Ther. 2008 Oct;24(5):453-9
pubmed: 18788995
ASN Neuro. 2019 Jan-Dec;11:1759091419871420
pubmed: 31450955
J Neurosci Res. 2002 Mar 15;67(6):795-803
pubmed: 11891794
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10659-64
pubmed: 12130665
Dtsch Arztebl Int. 2020 Mar 27;117(13):225-234
pubmed: 32343668
F1000Res. 2020 Sep 18;9:
pubmed: 32983414
Curr Eye Res. 2005 Nov;30(11):1025-31
pubmed: 16282136
Curr Eye Res. 2020 Dec;45(12):1504-1513
pubmed: 32339463

Auteurs

Ting-Yi Lin (TY)

Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
ORCID: 0000-0003-2067-9527

Yi-Fen Lai (YF)

Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
ORCID: 0000-0001-9166-7932

Yi-Hao Chen (YH)

Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.

Da-Wen Lu (DW)

Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Latest Evidence of Erythropoietin in the...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Érythropoïétine › The Latest Evidence of Erythropoietin in the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs aux facteurs de croissance hématopoïétique › Récepteur érythropoïétine › The Latest Evidence of Erythropoietin in the...
questionsmedicales.fr › Maladies de l'oeil › Hypertension oculaire › Glaucome › The Latest Evidence of Erythropoietin in the...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Érythropoïétine › Époétine alfa › The Latest Evidence of Erythropoietin in the...
questionsmedicales.fr › Cellules › Neurones › Neurones afférents › Neurones rétiniens › Cellules ganglionnaires rétiniennes › The Latest Evidence of Erythropoietin in the...